Establishment of radioactive astatine and iodine uptake in cancer cell lines expressing the human sodium/iodide symporter

Petrich, Thorsten; Hj, Helmeke; Gj, Meyer; Wh, Knapp; Pötter, Eyck

doi:10.1007/s00259-002-0784-7

Cited by 75 publications

(56 citation statements)

References 53 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Although all radioisotopes showed a rapid efflux, higher absorbed doses in the tumor were found for 211 At as compared to 131 I. 34 In conclusion, transfer of the sodium-iodide transporter gene into rat prostate adenocarcinoma cells together with the application of 131 I in clinically relevant amounts did not result in therapeutically useful absorbed doses in the NIS-expressing tumors in vivo. Further studies have to examine pharmacological modulation of iodide efflux or the use of the hNIS gene as an in vivo reporter gene.…”

Section: Transfer Of the Hnis Gene In Rat Prostate Carcinoma U Haberkmentioning

confidence: 76%

“…Furthermore, the high LET -emitter astatine-211 has been suggested as an isotope with high radiobiologic effectiveness. 15,34 First experiments showed that the tracer uptake in NISexpressing cell lines increased up to 350-fold for 123 I, 340-fold for 99m TcO 4 À and 60-fold for 211 At. Although all radioisotopes showed a rapid efflux, higher absorbed doses in the tumor were found for 211 At as compared to 131 I.…”

Section: Transfer Of the Hnis Gene In Rat Prostate Carcinoma U Haberkmentioning

confidence: 99%

See 1 more Smart Citation

Enhanced iodide transport after transfer of the human sodium iodide symporter gene is associated with lack of retention and low absorbed dose

et al. 2003

View full text Add to dashboard Cite

Section: Transfer Of the Hnis Gene In Rat Prostate Carcinoma U Haberkmentioning

confidence: 76%

Section: Transfer Of the Hnis Gene In Rat Prostate Carcinoma U Haberkmentioning

confidence: 99%

Enhanced iodide transport after transfer of the human sodium iodide symporter gene is associated with lack of retention and low absorbed dose

et al. 2003

View full text Add to dashboard Cite

“…Rhenium could be effective over a higher tissue range (23-32 mm), being effective also for treatment of large tumors (100,101). Further studies are needed in order to better define whether the use of rhenium can be more effective than that of 131 I. Astatine is an alfa-emitting radiohalide with a high linear energy, however its tissue range is short and its availability is scarce (102).…”

Section: Other Radioactive Isotopes Transported By Nismentioning

confidence: 99%

The importance of sodium/iodide symporter (NIS) for thyroid cancer management

Carvalho

Ferreira

2007

Arq Bras Endocrinol Metab

View full text Add to dashboard Cite

The thyroid gland has the ability to uptake and concentrate iodide, which is a fundamental step in thyroid hormone biosynthesis. Radioiodine has been used as a diagnostic and therapeutic tool for several years. However, the studies related to the mechanisms of iodide transport were only possible after the cloning of the gene that encodes the sodium/iodide symporter (NIS). The studies about the regulation of NIS expression and the possibility of gene therapy with the aim of transferring NIS gene to cells that normally do not express the symporter have also become possible. In the majority of hypofunctioning thyroid nodules, both benign and malignant, NIS gene expression is maintained, but NIS protein is retained in the intracellular compartment. The expression of NIS in non-thyroid tumoral cells in vivo has been possible through the transfer of NIS gene under the control of tissue-specific promoters. Apart from its therapeutic use, NIS has also been used for the localization of metastases by scintigraphy or PET-scan with 124 I. In conclusion, NIS gene cloning led to an important development in the field of thyroid pathophysiology, and has also been fundamental to extend the use of radioiodine for the management of non-thyroid tumors. A glândula tireóide tem capacidade de captar e concentrar iodeto, etapa fundamental na biossíntese dos hormônios tireóideos. O uso de iodo radioativo para fins de diagnóstico e terapia das doenças da tireóide vem sendo feito há muitos anos. Entretanto, somente após a clonagem do gene que codifica o cotransportador de sódio/iodeto (NIS) houve aumento significativo dos estudos relacionados ao mecanismo de transporte de iodeto. Os estudos sobre a regulação da expressão do NIS e a possibilidade de terapia gênica visando à transferência do gene NIS para células que normalmente não expressam esse transportador, foram também viabilizados. Na maior parte dos nódulos tireóideos hipofuncionantes, tanto benignos quanto malignos, a expressão do gene do NIS está presente, mas a proteína NIS fica retida no compartimento intracelular. A transferência do gene usando-se promotores tecido-específicos possibilitou a expressão do NIS em células tumorais não-tireóideas in vivo. Além do seu uso terapêutico, o NIS também vem sendo usado para a localização de metástases tumorais através da cintilografia ou do PET-scan usando-se 124 I. Em conclusão, a clonagem do NIS possibilitou enorme avanço na área de fisiopatologia tireóidea e foi também fundamental para estender o uso do radioiodo para tumores não tireóideos.

show abstract

“…Human SLC5A5 cDNA was cloned as described previously (Petrich et al 2002). Briefly, two overlapping cDNA fragments representing either the 5 0 -half or the 3 0 -half of the complete SLC5A5 coding region were amplified and inserted into pBluescript II KS (K) vector (Invitrogen) to create pBKS-SLC5A5-5 0 and pBKS-SLC5A5-3 0 plasmids respectively.…”

Section: Cloningmentioning

confidence: 99%

Histidine residue at position 226 is critical for iodide uptake activity of human sodium/iodide symporter

Wu¹,

Liang

et al. 2008

Journal of Endocrinology

View full text Add to dashboard Cite

The sodium/iodide symporter (SLC5A5; also known as NIS), a transmembrane glycoprotein principally in the thyroid gland, is responsible for the accumulation of iodide necessary for thyroid hormones. Our previous study indicated that a novel exon 6 deletion (residues 233-280) in SLC5A5 loses the iodide uptake activity. Herein we characterized the role of His-226 in iodide transport of SLC5A5. His-226, a highly conserved extracellular residue among SLC5A5 homologs, was replaced with alanine, aspartic acid, glutamic acid, or lysine. All the SLC5A5 mutants were expressed normally in the cells and targeted correctly to the plasma membrane. However, all of the mutants displayed severe defects in iodide uptake, suggesting that His-226 was critical for iodide uptake. Kinetic analysis further showed that mutation at His-226 led to a dramatic decrease in V max . These findings suggested that the decreased levels of iodide uptake activity of SLC5A5 mutants resulted from lower catalytic rates. In conclusion, our data first identified the involvement of extracellular charged amino acid residue in the iodide uptake ability of SLC5A5.

show abstract

Establishment of radioactive astatine and iodine uptake in cancer cell lines expressing the human sodium/iodide symporter

Cited by 75 publications

References 53 publications

Enhanced iodide transport after transfer of the human sodium iodide symporter gene is associated with lack of retention and low absorbed dose

Enhanced iodide transport after transfer of the human sodium iodide symporter gene is associated with lack of retention and low absorbed dose

The importance of sodium/iodide symporter (NIS) for thyroid cancer management

Histidine residue at position 226 is critical for iodide uptake activity of human sodium/iodide symporter

Contact Info

Product

Resources

About